CORZIDE- nadolol and bendroflumethiazide tablet

Maa: Yhdysvallat

Kieli: englanti

Lähde: NLM (National Library of Medicine)

Aktiivinen ainesosa:

NADOLOL (UNII: FEN504330V) (NADOLOL - UNII:FEN504330V), BENDROFLUMETHIAZIDE (UNII: 5Q52X6ICJI) (BENDROFLUMETHIAZIDE - UNII:5Q52X6ICJI)

Saatavilla:

Pfizer Laboratories Div Pfizer Inc

INN (Kansainvälinen yleisnimi):

NADOLOL

Koostumus:

NADOLOL 40 mg

Antoreitti:

ORAL

Prescription tyyppi:

PRESCRIPTION DRUG

Käyttöaiheet:

CORZIDE (Nadolol and Bendroflumethiazide Tablets) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with CORZIDE. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Ev

Tuoteyhteenveto:

CORZIDE (Nadolol and Bendroflumethiazide Tablets) Round, biconvex tablets are white to bluish white with dark blue specks. Each tablet has a full bisect bar. Tablet identification numbers: 40 mg/5 mg combination embossed with KPI/283 on the scored side and Corzide 40/5 on the other; 80 mg/5 mg combination embossed with KPI/284 on the scored side and Corzide 80/5 on the other. Keep bottle tightly closed. Store at room temperature; avoid excessive heat. Rx Only

Valtuutuksen tilan:

New Drug Application

Valmisteyhteenveto

CORZIDE- NADOLOL AND BENDROFLUMETHIAZIDE TABLET
PFIZER LABORATORIES DIV PFIZER INC
----------
CORZIDE® (NADOLOL AND BENDROFLUMETHIAZIDE TABLETS)
DESCRIPTION
CORZIDE (Nadolol and Bendroflumethiazide Tablets) for oral
administration combines two
antihypertensive agents: CORGARD (nadolol), a nonselective
beta-adrenergic blocking agent, and
NATURETIN (bendroflumethiazide), a thiazide diuretic-antihypertensive.
Formulations: 40 mg and 80
mg nadolol per tablet combined with 5 mg bendroflumethiazide. Inactive
ingredients: cellulose, colorant
(FD&C Blue No. 2), lactose, magnesium stearate, povidone, sodium
starch glycolate, and starch.
NADOLOL
Nadolol is a white crystalline powder. It is freely soluble in
ethanol, soluble in hydrochloric acid,
slightly soluble in water and in chloroform, and very slightly soluble
in sodium hydroxide. Nadolol is
designated chemically as
1-(_tert_-butylamino)-3-{(5,6,7,8-tetrahydro-_cis_-6,7-dihydroxy-1-naphthyl)oxy}-
2-propanol. Structural formula:
C H NO MW 309.4 0 CAS-4 2200-33-9
BENDROFLUMETHIAZIDE
Bendroflumethiazide is a white crystalline powder. It is soluble in
alcohol and in sodium hydroxide, and
insoluble in hydrochloric acid, water, and chloroform.
Bendroflumethiazide is designated chemically as
3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2_H_-1,2,4-benzothiadiazine-7-sulfonamide
1,1-dioxide.
Structural formula:
®
®
17
27
4
C H F N O S MW 4 21.4 1 CAS-73-4 8-3
CLINICAL PHARMACOLOGY
NADOLOL
Nadolol is a nonselective beta-adrenergic receptor blocking agent.
Clinical pharmacology studies have
demonstrated beta-blocking activity by showing (1) reduction in heart
rate and cardiac output at rest and
on exercise, (2) reduction of systolic and diastolic blood pressure at
rest and on exercise, (3) inhibition
of isoproterenol-induced tachycardia, and (4) reduction of reflex
orthostatic tachycardia.
Nadolol specifically competes with beta-adrenergic receptor agonists
for available beta receptor sites;
it inhibits both the beta receptors located chiefly in cardiac muscle
and the beta recept